[go: up one dir, main page]

WO2001046176A3 - Antagonistes de recepteur de tachykinine non peptidique - Google Patents

Antagonistes de recepteur de tachykinine non peptidique Download PDF

Info

Publication number
WO2001046176A3
WO2001046176A3 PCT/EP2000/013349 EP0013349W WO0146176A3 WO 2001046176 A3 WO2001046176 A3 WO 2001046176A3 EP 0013349 W EP0013349 W EP 0013349W WO 0146176 A3 WO0146176 A3 WO 0146176A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
tachykinin receptor
non peptide
peptide tachykinin
compounds
Prior art date
Application number
PCT/EP2000/013349
Other languages
English (en)
Other versions
WO2001046176A2 (fr
Inventor
David Christopher Horwell
Russell Andrew Lewthwaite
Martin Clive Pritchard
Jennifer Raphy
Hubert Barth
Klaus Steiner
Bernd Schiefermayr
Original Assignee
Warner Lambert Co
David Christopher Horwell
Russell Andrew Lewthwaite
Martin Clive Pritchard
Jennifer Raphy
Hubert Barth
Klaus Steiner
Bernd Schiefermayr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00103665A external-priority patent/EP1127875A1/fr
Priority to IL15020300A priority Critical patent/IL150203A0/xx
Priority to APAP/P/2002/002556A priority patent/AP2002002556A0/en
Priority to AU23708/01A priority patent/AU2370801A/en
Priority to MXPA02006282A priority patent/MXPA02006282A/es
Priority to BR0016626-0A priority patent/BR0016626A/pt
Priority to JP2001547086A priority patent/JP2003518111A/ja
Priority to EP00987477A priority patent/EP1244653A1/fr
Application filed by Warner Lambert Co, David Christopher Horwell, Russell Andrew Lewthwaite, Martin Clive Pritchard, Jennifer Raphy, Hubert Barth, Klaus Steiner, Bernd Schiefermayr filed Critical Warner Lambert Co
Priority to KR1020027008007A priority patent/KR20020062364A/ko
Priority to CA002399584A priority patent/CA2399584A1/fr
Priority to SK886-2002A priority patent/SK8862002A3/sk
Priority to PL00357650A priority patent/PL357650A1/xx
Publication of WO2001046176A2 publication Critical patent/WO2001046176A2/fr
Priority to IS6395A priority patent/IS6395A/is
Priority to BG106804A priority patent/BG106804A/xx
Priority to NO20022942A priority patent/NO20022942D0/no
Publication of WO2001046176A3 publication Critical patent/WO2001046176A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)

Abstract

La présente invention concerne des composés antagonistes de récepteur de tachykinine de formule (I), dans laquelle R, m, X, R1, R2, n, Y, R3, R4, R5 et R6 sont tels que décrits dans la description de l'invention. Ces composés sont des agents utiles pour traiter des états associés à une néovascularisation aberrante, telle que la polyarthrite rhumatoïde, l'athérosclérose et la croissance de cellules tumorales.
PCT/EP2000/013349 1999-12-22 2000-12-21 Antagonistes de recepteur de tachykinine non peptidique WO2001046176A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
PL00357650A PL357650A1 (en) 1999-12-22 2000-12-21 Non peptide tachykinin receptor antagonists
KR1020027008007A KR20020062364A (ko) 1999-12-22 2000-12-21 비펩티드 타키키닌 수용체 길항제
AU23708/01A AU2370801A (en) 1999-12-22 2000-12-21 Non peptide tachykinin receptor antagonists
MXPA02006282A MXPA02006282A (es) 1999-12-22 2000-12-21 Antagonistas de receptor de taquikinina no peptida.
BR0016626-0A BR0016626A (pt) 1999-12-22 2000-12-21 Antagonistas de receptor de taquinina não peptìdeo
JP2001547086A JP2003518111A (ja) 1999-12-22 2000-12-21 非ペプチドタキキニンレセプターアンタゴニスト
EP00987477A EP1244653A1 (fr) 1999-12-22 2000-12-21 Antagonistes de recepteur de tachykinine non peptidique
IL15020300A IL150203A0 (en) 1999-12-22 2000-12-21 Non peptide tachykinin receptor antagonists
SK886-2002A SK8862002A3 (en) 1999-12-22 2000-12-21 Non peptide tachykinin receptor antagonists
APAP/P/2002/002556A AP2002002556A0 (en) 1999-12-22 2000-12-21 Non Peptide Tachykinin Receptor Antagonists
CA002399584A CA2399584A1 (fr) 1999-12-22 2000-12-21 Antagonistes de recepteur de tachykinine non peptidique
IS6395A IS6395A (is) 1999-12-22 2002-05-24 Viðtaka mótlyf gegn kínínhröðun sem ekki eru peptíð
BG106804A BG106804A (en) 1999-12-22 2002-06-10 Non peptide tachykinin receptor antagonists
NO20022942A NO20022942D0 (no) 1999-12-22 2002-06-19 Ikke peptid tachykinin reseptor antagonister

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17154099P 1999-12-22 1999-12-22
US60/171,540 1999-12-22
EP00103665.6 2000-02-22
EP00103665A EP1127875A1 (fr) 2000-02-22 2000-02-22 Procédé de préparation de l'ester méthylique de l'alpha-diméthylaminométhyl-tryptophane

Publications (2)

Publication Number Publication Date
WO2001046176A2 WO2001046176A2 (fr) 2001-06-28
WO2001046176A3 true WO2001046176A3 (fr) 2002-07-04

Family

ID=26070578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/013349 WO2001046176A2 (fr) 1999-12-22 2000-12-21 Antagonistes de recepteur de tachykinine non peptidique

Country Status (18)

Country Link
EP (1) EP1244653A1 (fr)
JP (1) JP2003518111A (fr)
KR (1) KR20020062364A (fr)
CN (1) CN1413206A (fr)
AP (1) AP2002002556A0 (fr)
AU (1) AU2370801A (fr)
BG (1) BG106804A (fr)
BR (1) BR0016626A (fr)
CA (1) CA2399584A1 (fr)
IL (1) IL150203A0 (fr)
IS (1) IS6395A (fr)
MA (1) MA26854A1 (fr)
MX (1) MXPA02006282A (fr)
NO (1) NO20022942D0 (fr)
OA (1) OA12129A (fr)
PL (1) PL357650A1 (fr)
SK (1) SK8862002A3 (fr)
WO (1) WO2001046176A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105688A1 (en) 2007-01-24 2010-04-29 Glaxo Group Limited Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716979A (en) * 1992-08-13 1998-02-10 Warner-Lambert Company Tachykinin antagonists
WO2000037462A1 (fr) * 1998-12-18 2000-06-29 Warner-Lambert Company Antagonistes des recepteurs nk1 non peptidiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716979A (en) * 1992-08-13 1998-02-10 Warner-Lambert Company Tachykinin antagonists
WO2000037462A1 (fr) * 1998-12-18 2000-06-29 Warner-Lambert Company Antagonistes des recepteurs nk1 non peptidiques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOYLE S ET AL: "RATIONAL DESIGN OF HIGH AFFINITY TACHYKININ NK1 RECEPTOR ANTAGONISTS", BIOORGANIC & MEDICINAL CHEMISTRY,ELSEVIER SCIENCE LTD,GB, vol. 2, no. 5, 1994, pages 357 - 370, XP000917251, ISSN: 0968-0896 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002166079 *
HETEROCYCLES., vol. 26, no. 8, 1987, pages 2139 - 2151, ISSN: 0385-5414 *
LOVE B E ET AL: "A General Synthesis of 1-(Dialkylaminomethyl)indoles", SYNLETT,DE,THIEME VERLAG, STUTTGART, no. 10, 1998, pages 1123 - 1125, XP002143984, ISSN: 0936-5214 *
MACLEOD A M ET AL: "IDENTIFICATION OF L-TRYPTOPHAN DERIVATIVES WITH POTENT AND SELECTIVE ANTAGONIST ACTIVITY AT THE NK1 RECEPTOR", JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 37, no. 9, 1994, pages 1269 - 1274, XP000919224, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2001046176A2 (fr) 2001-06-28
CA2399584A1 (fr) 2001-06-28
MA26854A1 (fr) 2004-12-20
MXPA02006282A (es) 2004-09-06
AU2370801A (en) 2001-07-03
PL357650A1 (en) 2004-07-26
NO20022942L (no) 2002-06-19
IS6395A (is) 2002-05-24
BR0016626A (pt) 2002-11-05
IL150203A0 (en) 2002-12-01
BG106804A (en) 2003-03-31
EP1244653A1 (fr) 2002-10-02
JP2003518111A (ja) 2003-06-03
SK8862002A3 (en) 2002-11-06
CN1413206A (zh) 2003-04-23
AP2002002556A0 (en) 2002-06-30
NO20022942D0 (no) 2002-06-19
KR20020062364A (ko) 2002-07-25
OA12129A (en) 2006-05-05

Similar Documents

Publication Publication Date Title
BG106506A (en) ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a)-1,5-PYRIMIDINES AND PARAZOLO[1,5-a)-1,3,5-TRIAZINES
ATE347553T1 (de) Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
CA2293621A1 (fr) 4-aminopyrrole(3,2-d)pyrimidines en tant qu'antagonistes du recepteur du neuropeptide y
SE9702773D0 (sv) Novel compounds
WO2000059497A8 (fr) Modulateurs de pyrrolidine de l'activite du recepteur des chimiokines
IL147395A0 (en) Bradykinin b1 receptor antagonists
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
WO2000027846A3 (fr) Antagonistes de recepteurs du crf et methodes associees
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
PL341239A1 (en) Dihydrobenzofuranes
CA2237189A1 (fr) 3-azetidinylalkylpiperidines ou -pyrrolidines en tant qu'antagonistes des tachykinines
WO2001046176A3 (fr) Antagonistes de recepteur de tachykinine non peptidique
WO1998031704A3 (fr) Antagonistes de tachykinine
CA2244621A1 (fr) 4-amynopyrrole (3,2-d) pyrimidines comme antagonistes des recepteurs du neuropeptide y
AU1735200A (en) Novel isoxazoline fibrinogen receptor antagonists
HK1046284A1 (en) Polymorphs of crystalline azabicyclo(2,2,2)octan-3-aminecitrate and their pharmaceutical compositions.
WO2001007431A3 (fr) Derives de benzothiophene
SI1244614T1 (en) Tryptase inhibitors
WO2000007544A3 (fr) Antagonistes du recepteur de la proteine s
AU2001263329A1 (en) Crf receptor antagonists and methods relating thereto
HK1039332A1 (en) Piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907.
NZ516209A (en) Indoloazepines as vasopressin receptor antagonists
GB9911556D0 (en) Immunosuppressant tricyclic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 519125

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00670/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000987477

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20020373

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200200532

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2000 106804

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 150203

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 23708/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2002-2118

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 200204861

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: P20020533A

Country of ref document: HR

Ref document number: 8862002

Country of ref document: SK

Ref document number: 2399584

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/006282

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 547086

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027008007

Country of ref document: KR

Ref document number: 008175497

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: P-508/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1020027008007

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000987477

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: PV2002-2118

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000987477

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)